Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories

Page 2

Respirion inhales $14.2m
Cystic fibrosis drug developer Respirion Pharmaceuticals has spun out from Telethon Kids Institute with capital from an Australian government-backed initiative.
Big deal: Oxford PV begins capturing series D
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Gencove adds $3m to funding sequence
New York Genome Center-founded Gencove has added $3m from investors including Alexandria Venture Investments to bring its genomics testing kit to new markets.
Phasecraft executes funding
Based on UCL and Bristol research, Phasecraft is a member of a UK government-backed quantum collaboration driven by both universities together with the Google Quantum AI Lab.
Yunhu delivers series A-plus
The medical research services provider collected funding from investors including Cash Capital, an investment arm of CAS which previously backed a series A.
Sharpen phones IU in $15m round
IU Philanthropic Venture Fund was among the investors in the contact centre platform creator's round, which will help grow the business through recruitment and product development.
Well Doc recuperates with $1.6m
Scotiabank has supplied University of Calgary-affiliated Well Doc Alberta with funding under a pact signed when it bought MD Financial Management last year.
FanFood munches on $2m
The series A round reportedly featured UCLA Ventures, with the cash going towards expanding the business and technology for FanFood’s events concession app.
Parkwalk shifts return in Animal Dynamics
Parkwalk Advisors has sold on most of its stake in Oxford-founded drone designer Animal Dynamics, securing a 6.9 times return.
Yale endowment widens VC outlay
VC assets accounted for 19% of Yale’s endowment portfolio by June 2018 compared with 13.7% four years previously, as resources shifted away from leveraged buyouts and real estate.

test reg